Important Announcements

Nondiscrimination Policy Update

Boston Medical Center Health System complies with applicable Federal civil rights laws and does not discriminate on the basis of age, race, color, national origin (including limited English proficiency and primary language), religion, culture, physical or mental disabilities, socioeconomic status, sex, sexual orientation and gender identity and/or expression. BMCHS provides free aids and services to people with disabilities and free language services to people whose primary language is not English.

To read our full Nondiscrimination Statement, click here.

IRIS

Select your language:

IRIS: Insulin Resistance Intervention after Stroke Trial

Sponsor: NIH

Investigators: Carlos Kase MD (principal), Thanh Nguyen MD, Viken Babikian MD, Jose Romero MD, Aleksandra Pikula MD

Summary

Pioglitazone is a medication that improves insulin resistance, and is approved by the FDA for diabetes. Insulin resistance is a condition in which insulin, a normal human hormone, does not work effectively because the body is resistant to its effects. Insulin resistance can lead to diabetes and is thought to cause blood vessel disease, including stroke and heart attack in patients with and without diabetes. This study is designed to find out if a diabetes medication, pioglitazone, helps prevent recurrent stroke or heart attack among patients who have recently had a stroke or TIA.

Study enrollment completion in July 2015 and results pending.